C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
November 13, 2020 07:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys...
C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
November 12, 2020 16:05 ET
|
C4 Therapeutics, Inc.
– Strengthened leadership team with appointments of Andrew Hirsch as Chief Executive Officer, William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer – – Completed upsized...
C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit
October 14, 2020 07:30 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy...
C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 06, 2020 16:05 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy...
C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering
October 01, 2020 21:58 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy...